Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast Calculation
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Cardiovascular clinical trials industry 360º synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Phase trends
2.1.4 Study design trends
2.1.5 Indication trends
2.1.6 End-use trends
Chapter 3 Cardiovascular Clinical Trials market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising burden of cardiovascular diseases globally
3.2.1.2 Increasing number of contract research organizations (CROs)
3.2.1.3 Increasing R&D expenditure towards clinical trials
3.2.2 Industry pitfalls & challenges
3.2.2.1 Patient recruitment and retention challenges
3.2.3 Growth potential analysis
3.2.4 By phase
3.2.5 By study design
3.2.6 By indication
3.2.7 By end use
3.3 COVID-19 impact analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Cardiovascular Clinical Trials Market Estimates and Forecast, By Phase, 2018-2032 (USD Million)
5.1 Key trends, by phase
5.2 Phase I
5.3 Phase II
5.4 Phase III
5.5 Phase IV
Chapter 6 Cardiovascular Clinical Trials Market Estimates and Forecast, By Study Design, 2018-2032 (USD Million)
6.1 Key trends, by study design
6.2 Interventional
6.3 Observational
6.4 Expanded access
Chapter 7 Cardiovascular Clinical Trials Market Estimates and Forecast, By Indication, 2018-2032 (USD Million)
7.1 Key trends, by indication
7.2 Cerebrovascular disease
7.3 Coronary artery disease
7.4 Hypertensive heart disease
7.5 Cardiac arrhythmia
7.6 Inflammatory heart disease
7.7 Pulmonary arterial hypertension syndrome
7.8 Ischemic heart disease
7.9 Heart failure
7.10 Other indications
Chapter 8 Cardiovascular Clinical Trials Market Estimates and Forecast, By End Use, 2018-2032 (USD Million)
8.1 Key trends, by end-use
8.2 Biotechnology and pharmaceutical companies
8.3 Medical devices manufacturers
8.4 Contract research organization (CRO)
8.5 Other end users
Chapter 9 Cardiovascular Clinical Trials Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Eli Lilly & Company
10.2 IQVIA Inc
10.3 Worldwide Clinical Trials
10.4 ICON plc
10.5 Thermo Fisher Scientific (PPD Inc)
10.6 Syneos Health
10.7 Medpace, Inc.
10.8 Veeda Clinical Research
10.9 WuXi AppTech
10.10 Pfizer
10.11 Merck & Co
